A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)

NCT01709305 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

5570

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Metformin
DRUG: Sitagliptin
DRUG: Acarbose
DRUG: Repaglinide
DRUG: Glimepiride
DRUG: Gliclazide

Sponsor

Merck Sharp & Dohme LLC